


## Modipafant

Cat. No.:	HY-108908A
CAS No.:	122957-06-6
Molecular Formula:	C <sub>34</sub> H <sub>29</sub> ClN <sub>6</sub> O <sub>3</sub>
Molecular Weight:	605.09
Target:	Platelet-activating Factor Receptor (PAFR)
Pathway:	GPCR/G Protein
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



### BIOLOGICAL ACTIVITY

<b>Description</b>	Modipafant (UK-80067), the (+)-enantiomer of UK-74505, is a potent, orally active, and selective platelet-activating factor (PAF) antagonist. Modipafant exhibits approximately double the intrinsic potency of UK-74505 <sup>[1][2]</sup> .
<b>In Vitro</b>	when preincubated with rabbit platelets, the potency of antagonizing PAF induced aggregation increased markedly when preincubation time with Modipafant was increased from 2 min (IC <sub>50</sub> =5.6 nM) to 60 min (IC <sub>50</sub> =0.34 nM) <sup>[2]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

### REFERENCES

- [1]. Kuitert LM, et al. Effect of a novel potent platelet-activating factor antagonist, modipafant, in clinical asthma. *Am J Respir Crit Care Med*. 1995;151(5):1331-1335.
- [2]. Jezequel SG, et al, a new PAF antagonist: pharmacokinetics and disposition in rat, dog and man. *Xenobiotica*. 1996;26(9):963-975.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA